@ivorytrial.bsky.social
Pinned
The IVORY trial was published in Nature Medicine last week. rdcu.be/eX8W3
This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a
⬆️ Regulatory T cells
⬇️ Arterial inflammation 🔥
⬇️ trend in adverse cardiovascular outcomes ❤️🔥 at 2 years
This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a
⬆️ Regulatory T cells
⬇️ Arterial inflammation 🔥
⬇️ trend in adverse cardiovascular outcomes ❤️🔥 at 2 years
Reposted
New online! Low-dose IL-2 therapy reduces arterial inflammation in acute coronary syndromes #CardioSky
Low-dose IL-2 therapy reduces arterial inflammation in acute coronary syndromes
Nature Reviews Cardiology, Published online: 22 January 2026; doi:10.1038/s41569-026-01256-0Treatment with low-dose IL-2 increases regulatory T cell numbers and reduces arterial inflammation in patients with an acute coronary syndrome and residual systemic inflammation compared with placebo, according to findings from the IVORY trial.
dlvr.it
January 23, 2026 at 3:51 AM
New online! Low-dose IL-2 therapy reduces arterial inflammation in acute coronary syndromes #CardioSky
Reposted
In a phase 2 trial, low-dose interleukin-2 boosted regulatory T cells and reduced arterial inflammation in acute coronary syndrome patients compared to placebo.
https://www.nature.com/articles/s41591-025-04090-y
https://www.nature.com/articles/s41591-025-04090-y
January 17, 2026 at 5:40 PM
In a phase 2 trial, low-dose interleukin-2 boosted regulatory T cells and reduced arterial inflammation in acute coronary syndrome patients compared to placebo.
https://www.nature.com/articles/s41591-025-04090-y
https://www.nature.com/articles/s41591-025-04090-y
Reposted
Thank you Elisa Martini for featuring the IVORY trial published in @natmed.nature.com in Nature Portfolio’s Nature CVR 🫀
Main paper: rdcu.be/eX8W3
Commentary: rdcu.be/eYyG6
@jch403.bsky.social @ziadmallat.bsky.social @18fdg.bsky.social @ivorytrial.bsky.social @mallatlab.bsky.social
Main paper: rdcu.be/eX8W3
Commentary: rdcu.be/eYyG6
@jch403.bsky.social @ziadmallat.bsky.social @18fdg.bsky.social @ivorytrial.bsky.social @mallatlab.bsky.social
January 19, 2026 at 2:26 AM
Thank you Elisa Martini for featuring the IVORY trial published in @natmed.nature.com in Nature Portfolio’s Nature CVR 🫀
Main paper: rdcu.be/eX8W3
Commentary: rdcu.be/eYyG6
@jch403.bsky.social @ziadmallat.bsky.social @18fdg.bsky.social @ivorytrial.bsky.social @mallatlab.bsky.social
Main paper: rdcu.be/eX8W3
Commentary: rdcu.be/eYyG6
@jch403.bsky.social @ziadmallat.bsky.social @18fdg.bsky.social @ivorytrial.bsky.social @mallatlab.bsky.social
January 12, 2026 at 10:38 PM
The IVORY trial was published in Nature Medicine last week. rdcu.be/eX8W3
This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a
⬆️ Regulatory T cells
⬇️ Arterial inflammation 🔥
⬇️ trend in adverse cardiovascular outcomes ❤️🔥 at 2 years
This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a
⬆️ Regulatory T cells
⬇️ Arterial inflammation 🔥
⬇️ trend in adverse cardiovascular outcomes ❤️🔥 at 2 years
January 12, 2026 at 10:30 PM
The IVORY trial was published in Nature Medicine last week. rdcu.be/eX8W3
This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a
⬆️ Regulatory T cells
⬇️ Arterial inflammation 🔥
⬇️ trend in adverse cardiovascular outcomes ❤️🔥 at 2 years
This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a
⬆️ Regulatory T cells
⬇️ Arterial inflammation 🔥
⬇️ trend in adverse cardiovascular outcomes ❤️🔥 at 2 years